Vaccine to prevent EBV-linked lymphomas in people with HIV
Rational Vaccine Design to prevent HIV-Associated Lymphoma
A vaccine approach to prompt protective antibodies against Epstein-Barr virus so people living with HIV have a lower chance of developing EBV-driven lymphomas.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11295380 on NIH RePORTER |
What this research studies
This project aims to design a vaccine that teaches the immune system to make AMMO1-like antibodies that block Epstein-Barr virus (EBV), a key cause of many lymphomas in people with HIV. Researchers are focusing on viral surface proteins called gH/gL and testing different vaccine designs in the lab and in animal models to find ones that produce high levels of neutralizing antibodies. The team previously showed that giving the AMMO1 antibody protected humanized mice and rhesus macaques from EBV infection, and now they want a vaccine that makes the body produce similar antibodies on its own. If the vaccine candidates are promising, the plan would be to move toward studies that could include people at high risk for EBV-related lymphoma.
Who could benefit from this research
Good fit: People living with HIV—especially those with advanced immune suppression or who live in regions where EBV-related lymphomas are common—would be the eventual target population for this vaccine.
Not a fit: People whose lymphomas are not driven by EBV or individuals who already have active lymphoma are unlikely to benefit from a preventive EBV vaccine.
Why it matters
Potential benefit: If successful, this vaccine could lower EBV infections and reduce the risk of EBV-driven lymphomas in people living with HIV.
How similar studies have performed: Related work shows that passive transfer of the AMMO1 antibody protected mice and monkeys from EBV, but a broadly protective EBV vaccine for people—particularly those with HIV—has not yet been established.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Mcguire, Andrew — Fred Hutchinson Cancer Center
- Study coordinator: Mcguire, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.